

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2019

Predictive Oncology Inc.
(Exact name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-36790
(Commission File Number)

83-4360734
(IRS Employer Identification No.)

2915 Commers Drive, Suite 900
Eagan, Minnesota
(Address of Principal Executive Offices)

55121
(Zip Code)

Registrant's telephone number, including area code: **(651) 389-4800**

Former Name or Former Address, if Changed Since Last Report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.01 par value	POAI	Nasdaq Capital Market

Item 7.01 Regulation FD Disclosure.

On September 23, 2019, Predictive Oncology Inc. released a corporate presentation. The presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	<u>Presentation dated September 23, 2019</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PREDICTIVE ONCOLOGY INC.

By: /s/ Bob Myers
Name: Bob Myers
Title: Chief Financial Officer

Date: September 26, 2019



PREDICTIVE ONCOLOGY



Corporate Overview

Cancer Quest 2020 Project

September 2019

Forward looking statements

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes” and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market, regulatory, and other factors. A full discussion of our operations and financial conditions, including risk factors that may affect our business and future prospects, is contained in our most recent regulatory filings with the U.S. Securities and Exchange Commission (“SEC”), including our Form 10-K filed April 1, 2019 and our Form 10-Q filed on August 19, 2019.



Predictive Oncology – Who we are



Predictive Oncology (NASDAQ:POAI) is a data and AI-driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients.



Today

- Opportunity for Predictive Oncology to invest in precision medicine business with goal to **monetize** the assets within **18 months to have a valuation comparable to its peers of \$250 million.**
- For comparison: Tempus is valued at approx. \$1BN with \$320MM invested.
 - Continues to burn cash to build its asset.
- We have **HISTORICAL** data and assets that with investment we can leverage **TODAY**.
 - Competitors addressing cancer must **wait at least five years** to find out if the patient survived treatment before they can show value from their investments in gathering data.
- Our execution plan is founded on leveraging our two unique assets
 - A clinically validated patient-derived (PDx) tumor profiling platform that can generate **drug response profiles** and other multi-omic data. This platform had **over \$200M invested** and was clinically validated in ovarian cancer
 - Data on the **drug response** profiles of **over 150,000 tumors across 137 cancer types** tested using the PDx platform in **over 10+ years of clinical testing**
- The **Execution** risk is due to funding.....
- The **Development** risk is minimal because we already have the assets.
 - These assets are proven and exist today.
- Furthermore, **we can continue to generate more data every day** and have the ability to reach back to get more outcome data.




The Unmet Need In Precision Medicine



- Pharma has invested heavily in genomics and “big data” to understand each patient’s genome to target therapies
 - Success rates for targeted therapies are low
 - Uptake in clinical practice is patchy
- Realization now that “just genomics” is not enough
- A clear unmet need for a **multi-omic** (genome, transcriptome, epigenome, proteome, responseome and microbiome) approach, which may offer a greater chance of success, but such data is difficult to access quickly
 - Few comprehensive, multi-omic datasets exist
 - Need to initiate prospective data collection = time-consuming.



Building commercial value from our unique assets and collaborations



Unlike most companies in the space, we have samples and access to **historical** data (The Helomics asset) on clinical outcomes. Hence, we can **generate value to Pharma** much more quickly


Companies starting today **must wait** for that clinical outcome data at **least 5 years**

* Requires investment to sequence Helomics samples/access data from UK 100,000 genomes project




Helomics unique position on outcome data

- We have **HISTORICAL** data and assets that with investment we can leverage **TODAY**.
- Other companies in our space are spending \$\$ to generate data **TODAY** that they can't leverage until the **FUTURE**
- We have only to wait for **how long it takes to sequence** and gather outcome data which is **measured in months** not years
- For example in cancer you have to **wait at least 5 years** to see progression free survival rate.
- Sweet spot of **120,000** cases to access **10+ years** of survival data



Our testing data on tumors goes back 15+ years = key asset

Cancer Quest 2020 – key milestones



Application of Predictive Oncology Models

Research


- Biomarker discovery
- Drug discovery
- Drug-repurposing

Development

- Patient enrichment & selection for trials
- Clinical trial optimization
- Adaptive trials

Clinical Decision Support

- Patient stratification
- Treatment selection



Multi-omic models that predict drug response in tumors are highly value to Pharma




Commercialization: PDx, data and AI-driven Discovery Services

- To build AI models of tumor drug response of value to;
 - Pharma discovery and translational research projects
 - Highest value = Pharma contracts
 - Sales cycle 12-18 months
 - Contract value **(1M–5M)**
 - Collaborations and pilots
 - Earn short term revenue (\$50-\$250K)
 - Build commercial validation
- New precision medicine clinical tests for individualizing therapy in cancer
 - Longer term revenue opportunity
 - Clinical validation & regulatory approval required



Commercialization Roadmap – AI Predictive models



Because we have samples, drug response data and access to clinical outcomes going back over 7+ years investment is the only bottleneck in building models we can use in partnership with Pharma to look for new drugs/biomarkers for a range of cancers



Ovarian Model

Milestone	Item
Milestone #1	Sample extraction and library preparation (48 samples) Sequencing (48 samples) – outsource Additional compute costs Start reach-out to get lung outcomes
Milestone #2	Pay sequencing for 48 samples – outsource Sample extraction and library preparation (350 samples) Additional Slide digitization (outsource in short term) Upfront payments for Sequencing 350 samples Additional compute costs (bioinformatics analysis, Deep Learning GPU's and grids, storage (1 petabyte)
Milestone #3	Pay sequencing for 350 samples - outsource Additional compute costs (bioinformatics analysis, Deep Learning GPU's and grids, storage (1 petabyte) Additional data from Magee
Milestone #4	Compute costs (bioinformatics analysis, Deep Learning GPU's and grids, storage (1 petabyte) Web Infrastructure build out to deploy completed model Payments for lung outcome data
Milestone #5	Complete infrastructure build-out



Summary

- Opportunity for Predictive Oncology to invest in precision medicine business with goal to **monetize** the assets within **18 months to have a valuation comparable to its peers of \$250 million.**
- For comparison: Tempus is valued at approx. \$1BN with \$320MM invested.
 - Continues to burn cash to build its asset.
- We have **HISTORICAL** data and assets that with investment we can leverage **TODAY**.
 - Competitors addressing cancer must wait at **least five years** to find out if the patient survived treatment before they can show value from their investments in gathering data.
- Our execution plan is founded on leveraging our two unique assets
 - A clinically validated patient-derived (PDx) tumor profiling platform that can **generate drug response profiles** and other multi-omic data. This platform had **over \$200M invested** and was clinically validated in ovarian cancer
 - Data on the **drug response profiles** of **over 150,000 tumors across 137 cancer types** tested using the PDx platform in over **10+ years of clinical testing**
- The **Execution** risk is due to funding.....
- The **Development** risk is minimal because we already have the assets.
 - These assets are proven and exist today.
- Furthermore, **we can continue to generate more data every day** and have the ability to reach back to get more outcome data.





PREDICTIVE ONCOLOGY



Thank You

Cancer Quest 2020 Project

September 2019
